BioCentury
ARTICLE | Emerging Company Profile

Oricula: Preserving hearing

How Oricula looking to preserve hearing during aminoglycoside treatment

September 29, 2014 7:00 AM UTC

Oricula Therapeutics LLC is developing a small molecule from the University of Washington to prevent hearing loss in patients treated with aminoglycoside antibiotics. The small molecule could allow expanded use of the antibiotics, which are efficacious and inexpensive treatment options for serious infections.

Aminoglycosides such as streptomycin are used primarily to treat Gram-negative and Mycobacterium infections; however, nephrotoxicity and ototoxicity limit their use...